CRO Fortrea 'dis­putes the ac­cu­ra­cy' of Ace­lyrin's claims about im­munol­o­gy drug tri­al con­duct

Af­ter Ace­lyrin said that a con­tract re­search or­ga­ni­za­tion and its ven­dor made “clin­i­cal tri­al ex­e­cu­tion er­rors” in a study of the biotech’s lead im­munol­o­gy treat­ment can­di­date, the CRO has re­spond­ed and is push­ing back against some of the claims.

North Car­oli­na-based Fortrea, a large, decades-old CRO that re­cent­ly spun out of Lab­corp, said in an SEC fil­ing on Wednes­day that it “dis­putes the ac­cu­ra­cy of state­ments that ACE­LYRIN has made and the char­ac­ter­i­za­tion of those state­ments in sub­se­quent me­dia re­ports.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA